The physiological rationale for oral insulin administration

Diabetes Technology and Therapeutics

Volumn 6, Issue 4, 2004, Pages 510-517

  Arbit, Ehud ^a  

^a Emisphere Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ELIMINATION; DRUG TARGETING; DRUG TRANSPORT; GLYCEMIC INDEX; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TREATMENT FAILURE;

ADMINISTRATION, ORAL; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN;

EID: 4344640503     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/1520915041705929     Document Type: Review

References (54)

1. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-2012.
2. Harris M, Eastman R, Cowie C, Flegal K, Eberhardt M: Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999;22:403-408.
3. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S: Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA 1997;278:1663-1669.
4. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS: Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 1995;18:1113-1123.
5. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS: Intensive conventional insulin therapy for type II daiabetes:metabolic effects during a 6 months outpatient trial. Diabetes Care 1993;16:21-31.
6. Nathan DM: Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002;347:1342-1349.
7. Groop LC, Bonadonna RC, Del Prato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA: Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989;84:205-213.
8. Rizza RA, Mandarino LJ, Gerich JE: Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 1981;240:E630-E639.
9. Cherrington AD, Sindelar D, Edgerton D, Steiner K, McGuinness OP: Physiological consequences of phasic insulin release in the normal animal. Diabetes 2002;51(Suppl 1):S103-S108.
10. Cherrington AD: Control of glucose uptake and release by the liver in vivo [Banting Lecture]. Diabetes 1999;48:1198-1214.
11. Cryer PE, Davis SN, Shamoon H: Hypoglycemia in diabetes. Diabetes Care 2003;26:1902-1912.
12. Gerich J: Is muscle the major site of insulin resistance in type 2 (non-insulin-dependent) diabetes mellitus? Diabetologia 1991;34:607-610.
13. Paquot N, Scheen AJ, Dirlewanger M, Lefebvre PJ, Tappy L: Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients. Obes Res 2002;10:129-134.
14. Bavenholm PN, Pigon J, Ostenson CL, Efendic S: Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance. Diabetes 2001;50:1449-1454.
15. Gerich J: Control of glycaemia. Baillieres Clin Endocrinol Metab 1993;7:551-586.
16. DeFronzo RA, Bonadonna RC, Ferrannini E: Pathogenesis of NIDDM. Diabetes Care 1992;15:318-368.
17. Campbell PJ, Mandarino LJ, Gerich JE: Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism 1988;37:15-21.
18. Ferrannini E, Wahren J, Felig P, DeFronzo R: The role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man. Metabolism 1980;29:28-35.
19. Kelley D, Mitrakou A, Marsh H, Schwenk F, Benn J, Sonnenberg G, Arcangeli M, Aoki T, Sorensen J, Berger M: Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load. J Clin Invest 1988;81:1563-1571.
20. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, Gerich J: Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992;326:22-29.
21. Luzi L, DeFronzo RA: Effects of loss of first phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol 1989;257:E241-E246.
22. Bruce D, Chisholm D, Storlien L, Kraegen E: Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 1988;37:736-744.
23. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-794.
24. Polonsky KS, Given BD, Van Cauter E: Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988;81:442-448.
25. Pratley RE, Weyer CW: The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 2001;44:929-945.
26. Del Prato S, Marchetti P, Bonadonna RC: Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 2002;51(Suppl 1):S109-S116.
27. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti MC, Avogaro A, Tiengo A, Del Prato S: Restoration of early rise in plasma insulin level improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999;48:99-105.
28. Moore MC, Cherrington AD, Wasserman DH: Regulation of hepatic and peripheral glucose disposal. Best Pract Res Clin Endocrinol Metab 2003;17:343-364.
29. Broussolle C, Jeandidier N, Hanaire-Broutin H: French multicentre experience of implantable insulin pumps. The EVADIAC Study Group. Evaluation of Active Implants in Diabetes Society. Lancet 1994;343:514-515.
30. Hanaire-Broutin H, Broussolle C, Jeandidier N, Renard E, Guerci B, Haardt MJ, Lassmann-Vague V: Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study. The EVADIAC Study Group. Evaluation dans le Diabete du Traitement par Implants Actifs. Diabetes Care 1995;18:388-392.
31. Jeandidier N, Selam JL, Renard E, Guerci B, Lassman-Vague V, Rocher L, Hanaire-Broutin H: Decreased severe hypoglycemia frequency during intraperitoneal insulin infusion using programmable implantable pumps. Evadiac Study Group. Diabetes Care 1996;19:780.
32. Schade DS, Eaton RP: The peritoneum - a potential insulin delivery route for a mechanical pancreas. Diabetes Care 1980;3:229-234.
33. Selgas R, Diez JJ, Munoz J, Miranda B, deAlvaro F, Rodriguez JC: Comparative study of two different routes for insulin administration in CAPD diabetic patients. A multicenter study. Adv Perit Dial 1989;14:127-131.
34. Scarpioni L, Ballocchi S, Castelli A, Scarpioni R: Insulin therapy in uremic diabetic patients on continuous ambulatory peritoneal dialysis; comparison of intraperitoneal and subcutaneous administration. Perit Dial Int 1994;14:127-131.
35. Oskarsson PR, Lins PE, Backman L, Adamson UC: Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients. Diabetes Metab 2000;26:118-124.
36. Lahtela JT, Mustonen J, Pasternack A: Comparison of intraperitoneal and subcutaneous insulin administration on insulin sensitivity and serum lipids in type I diabetic patients on continuous ambulatory peritoneal dialysis treatment. Clin Sci 1995;88:427-432.
37. Lebovitz H: Insulin secretagogues: old and new. Diabet Rev 1999;7:139-153.
38. Moses R: A review of clinical experience with the prandial glucose regulator, repaglinide in the treatment of type 2 diabetes. Exp Opin Pharmacother 2001;1:1455-1467.
39. Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE: Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 2001;24:983-988.
40. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA: Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151-1167.
41. Vajo Z, Fawcett J, Duckworth WC: Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 2001;22:706-717.
42. Mathew PM, Young JM, Abu-Osba YK, Mulhern BD, Hammoudi S, Hamdan JA, Sa'di AR: Persistent neonatal hyperinsulinism. Clin Pediatr 1988;27:148-151.
43. de Lonlay-Debeney P, Poggi-Travert F, Fournet J-C, Sempoux C, Vici CD, Brunelle F, Touati G, Rahier J, Junien C, Nihoul-Fekete C, Robert JJ, Saudubray JM: Clinical features of 52 neonates with hyperinsulinism. N Engl J Med 1999;340:1169-1175.
44. Grimberg A, Ferry RJ Jr, Kelly A, Koo-McCoy S, Polonsky K, Glaser B, Permutt MA, Aguilar-Bryan L, Stafford D, Thornton PS, Baker L, Stanley CA: Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations. Diabetes 2001;50:322-328.
45. Stanley CA: Advances in diagnosis and treatment of hyperinsulinism in infants and children. J Clin Endocrinnl Metab 2002;87:4857-4859.
46. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, the Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.
47. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
48. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-2803.
49. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, Steen L, Westermark G, Westermark P, Orn T, Grill V: Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003;26:2231-2237.
50. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997;20:1353-1356.
51. Banerji MA, Lebovitz HE: Remission in non-insulin-dependent diabetes mellitus: clinical characteristics of remission and relapse in black patients. Medicine (Baltimore) 1990;69:176-185.
52. McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA: Near-normoglycaemic remission in African-Americans with type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med 2001;18:10-16.
53. Still G: Development of oral insulin: progress and current status. Diabetes Metab Res Rev 2002;(Suppl): S29-S37.
54. 2+ concentration. J Biol Chem 1998;273:33501-33507.